DOCSLIB.ORG

The Molecular and Cellular Biology of Thrombopoietin: the Primary Regulator of Platelet Production

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Molecular and Cellular Biology of Thrombopoietin: the Primary Regulator of Platelet Production Oncogene (2002) 21, 3359 ± 3367 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production Kenneth Kaushansky*,1 and Jonathan G Drachman1 1Division of Hematology, University of Washington School of Medicine, 1959 NE Paci®c Street, Seattle, Washington, WA 98195, USA The term thrombopoietin (TPO) was ®rst coined in 1958 represents the receptor binding domain (RBD) of the and used to describe the humoral substance responsible hormone; the carboxyl-terminal domain bears no for causing the platelet count to rise in response to resemblance to any known proteins, but contains thrombocytopenic stimuli. Despite much progress during multiple sites of both N- and O-linked carbohydrate the 1980s in the puri®cation and characterization of the (Homan et al., 1996). This latter feature accounts for humoral regulators of lymphocyte, erythrocyte, mono- the large discrepancy between the predicted and actual cyte and granulocyte production, the successful search to molecular weight of the protein; nearly 50% of the 70- purify and molecularly clone thrombopoietin did not kDa TPO molecule is carbohydrate. Like EPO, growth begin until the oncogene v-mpl was discovered in 1990. hormone and other members of the hematopoietic Since that time the proto-oncogene c-mpl was identi®ed growth factor family, the amino-terminal domain of and, based on homology arguments, believed to encode a TPO is predicted to fold into a left-handed four-helix hematopoietic cytokine receptor, a hypothesis later bundle protein, oriented up-up-down-down, with two proven when the cytoplasmic domain was linked to the overhand loops connecting the ®rst two and last two ligand binding domain of the IL-4 receptor and shown to helices (Wells, 1996). Our laboratory and others have support the IL-4 induced growth of hematopoietic cells demonstrated that the amino-terminal RBD of TPO is (Skoda et al., 1993). Finally, two dierent strategies adequate for receptor binding, signaling, and support- using c-mpl lead to the identi®cation of a novel ligand for ing cellular proliferation (Bartley et al., 1994; Linden the receptor in 1994 (de Sauvage et al., 1994; Lok et al., and Kaushansky, 2000). Several of the residues critical 1994; Bartley et al., 1994), a protein that displays all the for function of the hormone have been mapped in this biologic properties of TPO. This review attempts to region (Pearce et al., 1997; Park et al., 1998). Not distill what has been learned of the molecular and surprisingly, the human ± mouse inter-species homology cellular biology of TPO and its receptor during the past of TPO is greatest in the RBD (93%), although the several years, and links this information to several new carboxyl-terminal carbohydrate rich region retains insights into human disease and its treatment. 74% homology, suggesting that it also serves an Oncogene (2002) 21, 3359 ± 3367. DOI: 10.1038/j/onc/ important physiologic function. One such function is 1205323 to promote survival of the hormone in the circulation (Harker et al., 1996). Recently, our laboratory and Keywords: thrombopoietin; hematopoiesis; megakaryo- others have shown that this region also functions to cyte; signal transduction enhance secretion (Linden and Kaushansky, 2000; Muto et al., 2000). Molecular biology of thrombopoietin Molecular biology of Mpl Using three separate strategies ®ve groups puri®ed or Alternative splicing generates multiple forms of Mpl cloned TPO and reported their results in 1994 (reviewed in Kaushansky et al., 1995). The cloned The gene encoding the TPO receptor, c-mpl, is located human TPO cDNA predicts a polypeptide of 353 on human chromosome 1p34 and is composed of 12 amino acids including a 21 amino acid secretory leader exons (Mignotte et al., 1994). The corresponding sequence (Kaushansky, 1998), that can conveniently be murine gene is on chromosome 4 and has similar divided into two domains: the amino-terminal 154 organization and spice sites (Alexander and Dunn, residues of the mature polypeptide bear striking 1995). Variation in splicing at the 3' end of the sequence homology with erythropoietin (EPO) and molecule results in the formation of three distinct mRNA species in humans. The predominant form encodes the full-length protein (P-form) with a *Correspondence: K Kaushansky; transmembrane domain and 122 cytoplasmic residues. E-mail: [email protected] A second species of human Mpl mRNA is due to a The molecular biology of Mpl and TPO K Kaushansky and JG Drachman 3360 read through beyond the exon 10 splice donor site. The divided into two domains of seven b-strands, forming resulting K-form of the receptor, or Mpl-K, diverges antiparallel b-sheets (de Vos et al., 1992). Four from the native sequence after the ninth cytoplasmic conserved cysteine residues and a pentapeptide Trp- amino acid and terminates within intron 10 with 66 Ser-Xaa-Trp-Ser motif near the transmembrane do- predicted cytoplasmic residues (Vigon et al., 1992). main further characterize the CRM. Recent evidence This protein has no known biological activity, has not demonstrates that the membrane distal CRM exerts a been shown to transduce a proliferative signal, and negative regulatory role on signaling, as its deletion or could potentially act as a dominant negative receptor substitution results in constitutive proliferative signal- by heterodimerizing with Mpl-P after ligand binding. ing (Sabath et al., 1999). Despite extensive investiga- The third mRNA species, found in both human and tion, Mpl appears to function as a homodimer after murine cells, encodes a potentially secreted form of ligand binding, and does not form heterologous Mpl due to alternative splicing of exon 8 directly to signaling complexes with any of the known signaling exon 11, eliminating the juxtamembrane WSXWS chains (i.e. bc, gc and gp130). This stoicheometry is motif, the transmembrane domain, and the initial similar to that of the EPO, G-CSF, prolactin, and cytoplasmic residues (Vigon et al., 1992; Skoda et al., growth hormone receptors. 1993; Mignotte et al., 1994). It is not known whether Immediately downstream of the hydrophobic trans- this protein is actually secreted by hematopoietic cells membrane domain (25 residues) is a relatively short nor whether it is able to bind TPO. However, an signaling domain (121 amino acids in mice; 122 aa in engineered, puri®ed soluble form of Mpl has been humans). Although this portion of the receptor is well shown in vitro to bind exogenous TPO and block conserved across species (91% identity between murine cytokine activity (Kaushansky et al., 1995). Addition- and human proteins), it does not have signi®cant ally, alternative splice donor sites in exon 4 of murine homology to other known proteins. Like other mpl (but not human) result in the deletion of eight members of the hematopoietic cytokine receptor amino acids (24 nucleotides) in the extracytoplasmic family, the signaling region does not encode a tyrosine domain (Alexander et al., 1995). The signi®cance of kinase domain, tyrosine phosphatase, or other enzy- this altered form of the receptor is not known. matic functions. Therefore, all of the signaling events initiated by TPO binding to Mpl must be due to homodimerization and the recruitment of signaling The mpl promoter molecules to docking sites on the signaling complex The mpl promoter regulates lineage-speci®c expression (see below). on the cell surface of megakaryocytic precursors, mature megakaryocytes, platelets, and hematopoietic stem cells. Analysis of the promoter sequence reveals The regulation of thrombopoietin levels the presence of Ets, Sp1, and GATA-1 binding sites (Alexander et al., 1995; Deveaux et al., 1996; Mignotte The transient induction of severe thrombocytopenia et al., 1994). Transcription is not induced by any results in a relatively rapid restoration of platelet levels known external signals, such as the binding of TPO to followed by a brief period of rebound thrombocytosis. its receptor. Both a 700 and 200 nucleotide fragment of In both acute, antibody-mediated and myelosuppres- the human mpl promoter are sucient to direct sive therapy-induced thrombocytopenia, plasma con- lineage-speci®c expression in cell lines (Deveaux et al., centrations of TPO vary inversely with platelet counts, 1996; Mignotte et al., 1994) while a 2.0 kb fragment of rising to maximal levels within 24 hours of the onset of the murine mpl promoter is sucient to direct lineage- profound thrombocytopenia (Chang et al., 1996; speci®c expression in transgenic mice (Ziegler et al., Emmons et al., 1996). Two models have been advanced 1998). However, when cDNA encoding mpl was to explain the regulation of TPO levels. In the ®rst, transgenically expressed in mpl7/7 mice using the production of the hormone is constitutive, but its 2.0 kb promoter, the progeny had an unexpectedly consumption is determined by the mass of Mpl high platelet count (Ziegler et al., 1998 and our receptors accessible to the plasma (i.e. those present unpublished results). This result suggests that there on platelets and megakaryocytes (Kuter and Rosen- may be additional regulatory promoter elements up- berg, 1995; Stoel et al., 1996). In this way, stream of the 2.0 kb fragment or that the untranslated thrombocytopenia reduces peripheral blood TPO regions of mpl may modulate gene expression. destruction, resulting in elevated blood levels of the hormone, which drive megakaryopoiesis and platelet recovery. The weight of current evidence supports an The Mpl receptor is a homodimer important role for this mechanism in the regulation of The Mpl receptor is a type I transmembrane protein TPO production; platelets can deplete plasma of the and belongs to the hematopoietic cytokine receptor cytokine, TPO mRNA levels in the liver and kidney do superfamily. The extracytoplasmic domain, like the not vary in states of profound thrombocytopenia or common beta chain (bc) shared by the IL-3, IL-5, and thrombocytosis, and TPO knockout mice display a GM ± CSF receptors, is characterized by duplication of gene dosage eect indicating that active regulation of the cytokine receptor module (CRM).
Load more

Recommended publications
  • The Molecular Mechanisms That Control Thrombopoiesis
    The molecular mechanisms that control thrombopoiesis Kenneth Kaushansky J Clin Invest. 2005;115(12):3339-3347. https://doi.org/10.1172/JCI26674. Review Series Our understanding of thrombopoiesis — the formation of blood platelets — has improved greatly in the last decade, with the cloning and characterization of thrombopoietin, the primary regulator of this process. Thrombopoietin affects nearly all aspects of platelet production, from self-renewal and expansion of HSCs, through stimulation of the proliferation of megakaryocyte progenitor cells, to support of the maturation of these cells into platelet-producing cells. The molecular and cellular mechanisms through which thrombopoietin affects platelet production provide new insights into the interplay between intrinsic and extrinsic influences on hematopoiesis and highlight new opportunities to translate basic biology into clinical advances. Find the latest version: https://jci.me/26674/pdf Review series The molecular mechanisms that control thrombopoiesis Kenneth Kaushansky Department of Medicine, Division of Hematology/Oncology, University of California, San Diego, San Diego, California, USA. Our understanding of thrombopoiesis — the formation of blood platelets — has improved greatly in the last decade, with the cloning and characterization of thrombopoietin, the primary regulator of this process. Thrombopoietin affects nearly all aspects of platelet production, from self-renewal and expansion of HSCs, through stimulation of the proliferation of megakaryocyte progenitor cells, to support of the maturation of these cells into platelet-pro- ducing cells. The molecular and cellular mechanisms through which thrombopoietin affects platelet production provide new insights into the interplay between intrinsic and extrinsic influences on hematopoiesis and highlight new opportunities to translate basic biology into clinical advances.
    [Show full text]
  • Dr. Kenneth Kaushansky's Report to the University Senate April 6, 2020
    Dr. Kenneth Kaushansky’s report to the University Senate April 6, 2020 Dear Members of the Health Sciences Campus of Stony Brook University, I write today to update members of the Health Sciences Schools and Hospital on our efforts to overcome the COVID-19 pandemic, at least in Suffolk County and perhaps, far beyond. In short, we have mounted an amazing effort as the winds of the pandemic are building up, with ever- increasing numbers of infected individuals being identified. We have prepared for the coming “perfect storm.” And we have begun to model what the campus will look like when the flood waters begin to recede. And while our efforts to buffer the storm have been very well coordinated on many, many fronts, I will summarize our efforts by category. Disclaimer: What follows is a fairly detailed description of the efforts of hundreds of leaders from every corner of Stony Brook Medicine, from clinical to research, from basic to applied, from medical to nursing to technologists, and the spectacular response of several thousand members of the Renaissance School of Medicine (RSOM) and about 7,000 staff members of Stony Brook University Hospital (SBUH). For those who are faint of heart, or overtired (and hence already poised to nod off), please feel free to read as little of this note as you like! And if you are a numbers geek, you might be most interested in section 2, below. With that disclaimer aside, let me begin by explaining the basis for the coordination just mentioned, what I like to call the COVID choreography.
    [Show full text]
  • UW Medicine School of Medicine Science in Medicine Lecturers, 1993-Present
    UW Medicine School of Medicine Science in Medicine Lecturers, 1993-Present Presenter Name Lecture Type Year Department/Institution Lecture Title Francis S. Collins, M.D., Ph.D. Annual 1993-94 Center for Human Genome Research/NIH unknown Russell Ross, Ph.D. Distinguished Scientist 1993-94 Pathology unknown David Kimelman, Ph.D. New Investigator 1993-94 Biochemistry unknown Janice S. Blum, Ph.D. New Investigator 1993-94 Immunology unknown Michael W. Schwartz, M.D. New Investigator 1993-94 Medicine unknown Alan Chait, M.D. Science in Medicine 1993-94 Medicine unknown Christopher B. Wilson, M.D. Science in Medicine 1993-94 Immunology and Pediatrics unknown Neil M. Nathanson, Ph.D. Science in Medicine 1993-94 Pharmacology unknown Sheila A. Lukehart, Ph.D. Science in Medicine 1993-94 Medicine, Infectious Diseases unknown Susan Ott Ralph, M.D. Science in Medicine 1993-94 Medicine, Metabolism unknown Susan R. White, Ph.D. WWAMI 1993-94 Washington State University unknown Harold E. Varmus, M.D. Annual 1994-95 Director, NIH unknown Bertil Hille, Ph.D. Distinguished Scientist 1994-95 Physiology and Biophysics unknown Julie Overbaugh, Ph.D. New Investigator 1994-95 Microbiology unknown UW School of Medicine, Office of Research and Graduate Education For more information about the Science in Medicine lecture series contact [email protected] UW Medicine School of Medicine Science in Medicine Lecturers, 1993-Present Presenter Name Lecture Type Year Department/Institution Lecture Title Krzysztof Palczewski, Ph.D. New Investigator 1994-95 Ophthalmology unknown Mark A. Kay, M.D., Ph.D. New Investigator 1994-95 Medicine/Medical Genetics unknown Denise A. Galloway, Ph.D.
    [Show full text]
  • Hunting for Hematopoietic Transcriptional Networks COMMENTARY Kenneth Kaushanskya,1
    COMMENTARY Hunting for hematopoietic transcriptional networks COMMENTARY Kenneth Kaushanskya,1 Each day an adult human produces roughly 2.5 × 1011 thousands of platelets) at the site of blood vessel injury erythrocytes, 1 × 1011 leukocytes, and 1 × 1011 plate- and by providing an activated cell surface on which co- lets, numbers that can increase 10- to 20-fold in times agulation proteins (i) assemble and are activated, stabi- of heightened demand. Blood cell production, termed lizing the platelet plug, and (ii) together, initiate vascular hematopoiesis, occurs in the red marrow found mostly in healing. Without platelets, we hemorrhage. Platelets are the skull, spine, and proximal ends of the long bones of also involved in some of the most important diseases of the body. Within the marrow resides a small number of humans: By clotting on ruptured atherosclerotic plaques, hematopoietic stem cells (HSCs), the origin of all blood they cause myocardial infarction, stroke, and arterial in- cells, which undergo a series of proliferative and differ- sufficiency. By binding to circulating tumor cells, platelets entiation steps eventuating in the near half a trillion or promote metastatic spread of cancer. And when more cells produced each day. The molecular “wiring platelets are dysfunctional, they can cause pathological diagram” that regulates the production of mature blood clotting and hemorrhage. Thus, a thorough under- cells from HSCs is both cell intrinsic (gene transcription standing of platelet production—from the HSC to the factors and epigenetic changes) and cell extrinsic CMP, the MEP, the MkP, the megakaryocyte, and finally (growth factors and microenvironmental soluble and cell to circulating platelets—may shed light on a number surface proteins), although whether lineage decisions are physiological and pathological processes, as well as stochastic or directed by external factors remains a con- open doors into novel therapeutic approaches to troversial topic.
    [Show full text]
  • Primary Megakaryocytes Reveal a Role for Transcription Factor NF-E2
    Primary Megakaryocytes Reveal a Role for Transcription Factor NF-E2 in Integrin aIIbb3 Signaling Masamichi Shiraga,* Alec Ritchie,* Sallouha Aidoudi,* Veronique Baron,* David Wilcox,‡ Gilbert White,§ Belen Ybarrondo,i George Murphy,¶ Andrew Leavitt,¶ and Sanford Shattil* *Department of Vascular Biology, The Scripps Research Institute, La Jolla, California 92037; ‡Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226; §Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599; iPharMingen, Inc., San Diego, California 92139; and ¶Department of Laboratory Medicine, The University of California at San Francisco, San Francisco, California 94143 Abstract. Platelet integrin aIIbb3 responds to intracel- cient in the transcription factor NF-E2 failed to bind lular signals by binding fibrinogen and triggering cy- fibrinogen in response to agonists, despite normal toskeletal reorganization, but the mechanisms of surface expression of aIIbb3. Furthermore, while aIIbb3 signaling remain poorly understood. To better megakaryocytes from wild-type mice spread on immo- understand this process, we established conditions to bilized fibrinogen and exhibited filopodia, lamellipodia study aIIbb3 signaling in primary murine megakaryo- and Rho-dependent focal adhesions and stress fibers, cytes. Unlike platelets, these platelet precursors are NF-E2–deficient megakaryocytes adhered poorly. amenable to genetic manipulation. Cytokine-stimu- These studies establish that agonist-induced activation lated bone marrow cultures produced three arbitrary of aIIbb3 is controlled by NF-E2–regulated signaling populations of aIIbb3-expressing cells with increasing pathways that mature late in megakaryocyte develop- size and DNA ploidy: small progenitors, intermediate- ment and converge at the b3 cytoplasmic tail. Mega- size young megakaryocytes, and large mature mega- karyocytes provide a physiologically relevant and karyocytes.
    [Show full text]
  • University of California, San Diego
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Regulation of Thrombopoietin in Bone Marrow A Dissertation submitted in partial satisfaction of the Requirements for the degree Doctor of Philosophy in Biomedical Sciences by Bryan James McIntosh Committee in charge: Professor Kenneth Kaushansky, Chair Professor Gerald Boss Professor Christopher Glass Professor Lawrence Goldstein Professor Sanford J. Shattil 2007 Copyright Bryan James McIntosh, 2007 All rights reserved The dissertation of Bryan James McIntosh is approved, and is acceptable in quality and form for publication on microfilm: (Chair) University of California, San Diego 2007 iii TABLE OF CONTENTS Signature Page……………………………………………….………………………….. iii Table of Contents……………………………………………………………....……...... iv List of Figures………………………………………………………………...………….. v List of Schemes ……………………………………………………………….………… vi List of Tables …………………………………………………………..………………... vii List of Graphs ……………………………………………………………..…………….. viii Acknowledgements …………………………………………...…………………………ix Vita…………………………………………..………………………..………..………… x Abstract……………………………………………………………………..……..…….. xi Chapter1: Introduction and Background……………………………………..……… 1 Chapter 2: Transcriptional Regulation of Bone Marrow TPO by Platelet Proteins…………………………………………………………………...…6 Chapter 3: The Effect of Plasma on Bone Marrow TPO Expression…………………………………………………………………………….….26 Chapter 4: Alternative Hypotheses of TPO Regulation………………………….…..28 Chapter 5: Consideration of Potential Effects of Translation of TPO Transcript Stability ……………….……………….………....…...31 Chapter
    [Show full text]
  • ASCI Presidential Address Mentoring and Teaching Clinical Investigation
    ASCI Presidential Address Mentoring and teaching clinical investigation Kenneth Kaushansky J Clin Invest. 2004;114(8):1165-1168. https://doi.org/10.1172/JCI23462. ASCI Presidential Address Supplement A man walking along a road comes across three bricklayers. When asked what he is doing, the first bricklayer replies, “I am laying bricks.” When asked the same question, the second bricklayer answers, “I am making my living.” When asked what he is doing, the third bricklayer steps back, looks around, and responds, “I am building a cathedral.” It is my great privilege and pleasure to address the ninety-sixth annual meeting of the American Society for Clinical Investigation. I will begin with many thanks: to the council members who provide sage advice and a critical eye; to our staff, who provide dedicated direction and a keen sense of corporate memory; to the members of the ASCI in 2001, who felt it appropriate that I serve on the ASCI Council; and to the Presidents who have come before for providing the insights and precepts that have helped shape our Society into an organization of extremely dedicated men and women that continues as the leading advocate for scholarship in medicine. I will also try to follow the advice of the seventeenth-century Catalan philosopher Baltasar Gracian, who stated, “What is good, is doubly so if it be short; and in like manner, what is bad, is less so if there be little of it.” Most recent Presidential Addresses have begun with a palpable […] Find the latest version: https://jci.me/23462/pdf Supplement ASCI Presidential Address Mentoring and teaching clinical investigation Kenneth Kaushansky, M.D.
    [Show full text]
  • Frontiers of Chemical Biology and Drug Discovery: Nucleic Acid-Based Medicine”
    FOURTEENTH A N N U A L S Y M P O S I U M Institute of Chemical Biology & Drug Discovery “Frontiers of Chemical Biology and Drug Discovery: Nucleic Acid-Based Medicine” ........................................................................................................................ Thursday, October 8, 2020 Via Zoom ......................................................................................................................... Distinguished Speakers Dr. George A. Calin, The University of Texas MD Anderson Center Dr. Richard I. Gregory, Harvard University Dr. Lin He, University of California Berkeley Research Dr. Jingfang Ju, Stony Brook University Dr. Adrian Krainer, Cold Spring Harbor Laboratory Dr. Vivek Mittal, Weill Cornell Medicine Dr. Jennifer C. Petter, Arrakis Therapeutics Poster Sessions Poster Awards Stony Brook University/SUNY is an affirmative action, equal opportunity educator and employer. 10090247 ICB&DD 14th Annual Symposium Thursday, October 8, 2020 via Zoom Join Zoom Meeting https://stonybrook.zoom.us/j/92056653486?pwd=UlRIb00weWFSZzFFSEVjZFRGZy85UT09 Meeting ID: 920 5665 3486 Passcode: 300041 “Frontiers of Chemical Biology and Drug Discovery: Nucleic Acid-Based Medicine” 9:15 am to 9:30 am Opening Remarks Dr. Jingfang Ju, Professor of Pathology, Stony Brook University Renaissance School of Medicine. Chair, Symposium Organizing Committee Dr. Kenneth Kaushansky, Dean, Stony Brook University Renaissance School of Medicine Dr. Iwao Ojima, Distinguished Professor and Director, Institute of Chemical Biology
    [Show full text]
  • A Tribute to Helen M. Ranney
    A tribute to Helen M. Ranney Kenneth Kaushansky J Clin Invest. 2010;120(7):2250-2250. https://doi.org/10.1172/JCI43631. Obituary Helen Ranney, research and clinical hematologist extraordinaire, pioneering chair of medicine, professional society president, and soaring intellect, passed away on April 5, 2010, just a week before her 90th birthday (Figure 1). Helen was born and raised on a dairy farm in upstate New York to parents who encouraged her to seek a professional career. Helen’s mother was also raised on a farm in upstate New York and was encouraged by her mother to attended teachers’ school, ultimately working in the same one-room schoolhouse that Helen had attended for five years in order to send Helen and her brother to college. While setting out in pre-law studies at Barnard College, Helen soon found she liked working with people and “fixing what you studied” and therefore redirected her efforts toward pre-medical studies. Though she was admitted to New York University School of Medicine, Helen had her heart set on Columbia University College of Physicians and Surgeons but was initially refused admission. Instead, Helen sought out research training at Columbia with Donovan McCune, who inspired her lasting interest in medical research. With the arrival of World War II and with McCune’s strong support, Helen was admitted to Columbia, where she also completed her residency in internal medicine. After completing her clinical training, Helen studied biochemistry with Irving London, focusing her newly developed […] Find the latest version: https://jci.me/43631/pdf Obituary A tribute to Helen M.
    [Show full text]
  • Position Description
    Position Description Stony Brook University Senior Vice President, Health Sciences Prepared by: Bernard Godley, MD, PhD Ira Isaacson, MD, MBA Anne Neubauer Senior Vice President, Health Sciences, Stony Brook University The Opportunity Senior Vice President, Health Sciences Stony Brook University has engaged AMN Leadership Solutions to conduct a national search for the position of Senior Vice President, Health Sciences, Stony Brook Medicine. After 11 productive years, Kenneth Kaushansky, MD, is stepping down from his combined roles as Senior Vice President, Health Sciences and Dean of the Renaissance School of Medicine, leaving the thriving institution poised for significant growth in the years to come. Over the last 5 years, Stony Brook Medicine has grown from a solitary university hospital to a health system encompassing a pediatric hospital and 2 community hospitals on the eastern end of Long Island. Over the same period, the FT faculty numbers have grown by 50% to 1200, and the revenues from the hospitals, practice plan and IPA exceed $2.5 Billion. As the #1 ranked public medical school in the State of New York it is part of Stony Brook University, one of 65 members of the Association of American Universities (AAU), the invitation-only organization of the best research universities in North America. SBM engages in world-class, National Institutes of Health-sponsored research programs in neurological diseases, cancer, cardiovascular disorders, biomedical imaging, regenerative medicine and infectious diseases, among many other topics; has seen a 25 percent increase in research funding since 2010; and is awarded approximately $90 million in funded research annually. Four major past innovations by Stony Brook researchers include: 1) developing the Nobel Prize-winning technology that led to the MRI; 2) participating in the development of the technology for PET scans; 3) creating technology for 3D virtual colonoscopy; and 4) discovering the cause of Lyme disease.
    [Show full text]
  • University Senate Report November, 2020 Health Sciences Campus Kenneth Kaushansky MD, MACP
    University Senate Report November, 2020 Health Sciences campus Kenneth Kaushansky MD, MACP Stony Brook University Hospital System SBUH continues to prepare for a second round of COVID-19. The hospital is prepared with sufficient personal protective equipment, we have a robust plan for providing sufficient beds of all levels of acuity, our viral testing capacity has been greatly improved compared to early in the pandemic (see RSOM below), we have sufficient equipment (e.g. ventilators) and medications (e.g. glucocorticoids, remdesivir, convalescent plasma), and our staff are prepared well, based on our prior experiences. A second round of COVID-19, however, might be even more complex as it will likely overlap with influenza season, making diagnosis a bit more complex, but also bringing far more persons to our emergency department as has been the case during flu seasons of the past, when most people would stay home and do fine. When COVID overlaps with influenza, individuals with upper respiratory symptoms are now much more likely to be seen in our ED. At present, our total SBUH census is normal for this time of year (~590-620) with only 10-12 patients per day carrying a diagnosis of COVID-19. Finally, we have a plan to handle and distribute SARS-CoV2 vaccine when available. Renaissance School of Medicine In response to the expected increased patient volume at SBUH and in our outpatient facilities, and due to the needs of our campus for surveillance screening of faculty, staff and students, the pathology department has worked with a local biotech company to create a high volume, pooled sample surveillance testing protocol, that should be available for the upcoming semester.
    [Show full text]
  • December Commencement
    DECEMBER COMMENCEMENT STONY BROOK UNIVERSITY DECEMBER 18, 2020 COMMENCEMENT MESSAGE To all our graduates, Congratulations, graduates. In a year like no other — one that will go down in history for its unparalleled challenges and acts of heroism and innovation — we are incredibly proud of your accomplishments. You have earned a degree from one of the finest universities in the world: an institution renowned for its significant contributions to the advancement of science; leadership and ingenuity in the arts, humanities, and critical thought; steadfast commitment to local communities; and unwavering dedication to upholding the values of diversity, equity, and inclusion. With grace and grit, you have grown into the next generation of leaders and have the opportunity to make a profound difference in our community, our country, and our world. I hope that you will always keep in your heart the inspiring resilience you have shown here at Stony Brook University, and I hope you are always proud of the way you worked to foster an environment of care, respect, and civility even in the most difficult of situations. As you join our more than 200,000 alumni from around the globe, we hope you, like them, will consider Stony Brook University a continuing resource, even a second home, wherever your bright future leads. We wish you all the best, Seawolves, and I want to extend my sincerest gratitude and respect for all you have achieved. Maurie McInnis President H1 TABLE OF CONTENTS University Leadership ............................................................................................................................................
    [Show full text]